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performance testing and development of a micro-calorimeter 
based on Superconducting QUantum Interference Devices 
(SQUIDs) (1). Unlike other microdosimetric detectors that are 
used for investigating the energy distribution, this detector 
provides a direct measurement of energy deposition at the 
micrometer scale, that can be used to improve our 
understanding of biological effects in particle therapy 
application, radiation protection and environmental 
dosimetry. Temperature rises of less than 1µK are detectible 
and when combined with the low specific heat capacity of 
the absorber at cryogenic temperature, extremely high 
energy deposition sensitivity of approximately 0.4 eV can be 
achieved (2).  
The detector consists of 3 layers: a tissue equivalent (TE) 
absorber, a superconducting absorber and a silicon substrate. 
Ideally all energy would be absorbed in the TE absorber and 
heat rise in the superconducting layer would arise due to 
heat conduction from the TE layer. However, in practice 
direct particle absorption occurs in all 3 layers and must be 
corrected for. 
To investigate the thermal behavior within the detector, and 
quantify any possible correction, particle tracks were 
simulated employing Geant4 (v9.6) Monte Carlo simulations. 
The track information was then passed to the COMSOL 
Multiphysics (Finite Element Method) software. The 3D heat 
transfer within each layer was then evaluated in a time-
dependent model. For a statistically reliable outcome, the 
simulations had to be repeated for a large number of 
particles. An automated system has been developed that 
couples Geant4 Monte Carlo output to COMSOL for 
determining the expected distribution of proton tracks and 
their thermal contribution within the detector.  
Preliminary results of a 3.8 MeV proton beam showed that 
the detector reaches the equilibrium state after 8 ns.  It is 
estimated that 20% of the temperature rise in the 
superconducting absorber is due to heat conduction from the 
adjacent absorber which needs to be corrected for. The 
simulations were repeated for proton beams with energies of 
2, 10, 62 and 230 MeV. 
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Purpose: Nowadays, during the evaluation process of patient 
treatment plans in radiotherapy, the plan robustness is 
typically not taken into account. This evaluation of 
treatment plans can be improved if a user friendly and 
efficient tool to assess the robustness of the treatment plan 
is provided. Thus, the aim of this work is to develop tools and 
methods to quantify and visualize the robustness for 
treatment plans including random and systematic patient 
setup uncertainties. 
Materials and Methods: A setup error phase-space including 
systematic and random setup errors for translation and 
rotation is explored to determine the treatment plan 
robustness. For this purpose a robustness-map is created 
based on user-defined criteria defining the robustness for the 
treatment plan considered. These criteria subdivide the 
robustness-map for the setup error phase-space into a region 
compatible with these criteria and into another one that is 
not. Several different approaches were implemented to 
quantify the plan robustness. One approach transforms the 
optimized dose distribution relatively to the patient 
geometry and, thus, dosimetric parameters or DVHs can be 
quickly estimated, but are limited with respect to accuracy. 
Hence, approaches using further dose calculations for the 
setup error phase space are needed to achieve reliable 
conclusions of the robustness. For this purpose, additional 
dose calculations using a different resolution of the setup 
error phase-space are performed guided by the robustness-
map achieved using the dose-transformation approach. The 
intermediate dose distributions are determined by nearest 
neighbor or triangular interpolation. 
Results: A graphical user interface based on QT version 5.3.1 
was developed to calculate and visualize robustness-maps. 
These robustness-maps allow treatment plan evaluation by 
analyzing the corresponding dose-differences and DVHs. 
Additionally, correlations of all quantities can be displayed 
such that the user is able to efficiently view the data by 
scrolling through the setup error phase-space. The creation 
of robustness-maps is useful to assess and compare the 
robustness of different treatment plans and was successfully 
applied to plans covering different tumor-sites. For the cases 
investigated in this work, differences in DVH parameters 
using the different approaches are within 5%. 
Conclusions: The developed tool for visualization and analysis 
of robustness-maps is an easy and efficient way to compare 
the robustness of treatment plans. Moreover, clinical 
tolerance and action levels for patient setup can be 
determined in order to keep specified dosimetric parameters 
within a certain limit. This work was supported by Varian 
Medical Systems. 
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Purpose: In this paper we report the preliminary results of 
clinical use of organ motion mitigation strategies in the 
treatment of moving target with active scanned carbon ion 
beams. 
Material and methods: Since September 2014 25 patients 
with tumors located in the upper abdomen and chest were 
treated with active scanned carbon ion beams. 
Patients were affected by pancreatic adenocarcinoma, HCC, 
biliary tract cancers and sarcoma of the spine 
retroperitoneum and heart. Tight thermoplastic mask was 
selected as the optimal abdominal compression device. 4D CT 
scan with retrospective reconstruction, with phase signal 
obtained with Anzai system (Anzai Medical CO., LTD), was 
employed for planning.  Automatic assignment of raw data to 
respiratory phases was checked and, if necessary, modified 
by the medical physicist.  Planning was performed using end 
expiration phase. Planning CT scan were visually checked for 
motion artifacts. Contouring was performed on end 
expiration phase and on the adjacent 30% expiration and 30% 
inspiration phases. Beam entrance was selected in order to 
avoid the bowel in the entrance channel. The lung diaphragm 
interface was contoured in the different respiratory phases 
and beam angles were chosen to avoid passing tangential to 
the lung diaphragm ITV. IMPT was used for plan optimization. 
Plans were recalculated in adjacent phases and if DVHs were 
degraded in an unacceptable way they were modified 
iteratively. Weekly verification 4D CT scans were performed 
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and, if needed, a new plan was re-optimized adaptively.  Set 
up was verified with gated orthogonal X rays and non-gated 
cone beam CT in treatment room. Threshold for gate-on 
signal was initially set at 10% pressure signal dynamic and 
qualitatively adjusted in an asymmetric way according to 
results of plan recalculation in 30% expiration and 
inspiration. Gating signal was fed to the accelerator to 
enable beam delivery. Each slice was re-scanned 5 times to 
smear out possible interplay effects.  Acute and early toxicity 
was scored according to CTCAE 4.0 scale. 
Results: GTV and diaphragm excursion between end 
expiration and adjacent 30% phases was reduced to less than 
5 mm. GTV (D95%) and critical OAR (D1%)  DVH in 30% 
inspiration and expiration phases showed on average minimal 
(less than 3%) differences as compared to planning end 
expiration plan. Toxicity was minimal with no G3 event; 15% 
acute G2 and 10% G2 toxicity at 3 months was observed. 
Median follow up was rather short (3 months) nevertheless in 
23 patients the dose limiting OAR was either stomach or 
small bowel or esophagus, therefore early toxicity data are 
informative. 
Conclusion: Active scanning with carbon ion beams for the 
treatment of moving target using abdominal compression, 4D 
simulation, robust planning gating and rescanning is feasible 
and safe. Longer follow up is needed to evaluate oncological 
outcome 
 
Keywords: organ motion, active scanning 
 
86 
Carbon ion radiotherapy: do we understand each other? 
How to compare differentt RBE-weighted dose systems in 
the clinical setting. 
P. Fossati12, S. Molinelli1 ,G. Magro1, A. Mairani1, N. 
Matsufuji3, N. Kanematsu3, A. Hasegawa3, S. Yamada3, T. 
Kamada3, H. Tsujii3, M. Ciocca1, R. Orecchia1,2 
1 Fondazione CNAO,  Pavia, Italy. 
2 European Institute of Oncology, Milnao , Italy 
3 National Institute of Radiological Sciences, Chiba, Japan 
 
In carbon ion radiotherapy (CIRT), mainly two calculation 
models are adopted to define relative biological 
effectiveness (RBE)-weighted doses (DRBE): the Japanese 
Kanai model and the Local Effect Model (LEM). Taken the 
Japanese longest-term clinical data as a reference, the use 
of a different RBE model, with no correction for the Gy (RBE) 
scale, leads to deviations in target absorbed dose (Dabs) with 
a potentially significant impact on tumor control probability. 
In this study we validate a conversion method linking the two 
DRBE systems, confirming DRBE prescription dose values 
adopted in our LEM-based protocols.  
The NIRS beamline was simulated with a Monte Carlo (MC) 
code, according to design information about elements 
position, size and composition. Validation went through 
comparison between simulated and measured pristine and 
Spread Out Bragg Peaks, ridge filter based, in water. CT 
scan, structure set, plan and dose files of 10 treatment fields 
delivered at NIRS were exported in DICOM format, for 
prostate (3.6 Gy (RBE)NIRS per 16 fractions), Head & Neck (4 
Gy (RBE)NIRS per 16 fractions) and pancreas (4.6 Gy (RBE)NIRS 
per 12 fractions) patients. Patient specific passive system 
geometries (range shifter, MLC, compensator, collimator) 
were implemented, for each field, to simulate delivered Dabs 
distributions. The MC code was then interfaced with LEM to 
calculate DRBE resulting from the application of a different 
RBE model to NIRS physical dose. MC and TPS calculated Dabs 
and DRBE were compared in terms of dose profiles and target 
median dose. Patient CT and structure sets were also 
imported in a LEM-based commercial TPS where plans were 
optimized prescribing the non-converted and converted DRBE 
values, respectively. 
The agreement between MC and measured depth dose 
profiles in water, in terms of particle range, peak to plateau 
ratio and spread out profile shape, demonstrated beamline 
model accuracy. Patient dose distributions were correctly 
reproduced by MC in the target region, with an overall target 
median dose difference < 2%. MC median DRBE resulted 16% 
higher than NIRS reference, for the lower prostate dose 
level, 10% for head and neck and 4.5% for pancreas, in 
agreement with respective LEM-based prescription doses, 
adopted in our protocols. Deviations are expected to be close 
to zero around a prescription DRBE = 5 Gy (RBE). Aside from 
unavoidable differences in dose profile shape, severe target 
under-dosage was shown in LEM-based optimized plans, when 
uncorrected DRBE were prescribed.  
The delivery of a voxel by voxel iso-effective plan, if 
different RBE models are employed, is not feasible; it is 
however possible to minimize differences in dose deposited 
in the target. Dose prescription is a clinical task which 
ultimately depends only on the radiation oncologist clinical 
decision; in this study we made an attempt to avoid 
systematic errors which could potentially compromise tumor 
control.  
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Purpose: The aim of this study is to compare the radiation 
induced DNA damage done by internal Auger-electron 
cascades with external exposures of sparsely ionizing 
radiation such as γ-rays.  
Background: Auger emitters decay by internal conversion (IC) 
or electron capture (EC) producing a number of Auger 
cascade electrons. These electrons are so low in energy that 
their range in tissue is in the order of nm-μm. This means 
that if the decay happens nearby the DNA, the Auger cascade 
electrons can produce a cluster of complex DNA damage. 
These clusters of DNA damage are much harder to repair and 
are therefore believed to be much more harmful to the cell 
than dispersed DNA damage, which are primarily produced by 
low LET radiation. Due to their short tissue range and the 
severe DNA damage produced, Auger emitters may be able to 
kill only the target cell while sparing non-targeted cells. This 
makes them a potential tool for radionuclide 
therapy(1,2,3,4). 
Material/Methods: In order to compare the radiation effects 
by the Auger emitter to that of external γ-rays we need to be 
able to estimate the dose delivered. As Auger cascade 
electrons have a very short range the precise spatial 
distribution of the decays is of high importance. 
We are currently working with two Auger emitters, Cs-131 
and La-135. First experiments have been performed using 
HeLa cells, which were incubated with either Cs-131 or La-
